Why the study?
Atrial fibrillation is common in patients with ATTR-CA, but the optimal strategy to prevent strokes in this population is unknown.
Do novel oral anticoagulants (NOACs) reduce the composite of stroke, TIA, major bleed, or death compared to warfarin in adults with transthyretin cardiac amyloidosis and atrial fibrillation?
Population
290 patients with ATTR-CA, including 217 with AF
Comparison
Warfarin vs NOACs
Design
Retrospective analysis
Follow-up
Mean 2.4 years (range 0.1–12)
Authors
Loading...
No difference seen in this observational cohort; leaves open whether randomized trials would favor NOACs in transthyretin amyloidosis with AF.
Do novel oral anticoagulants (NOACs) reduce the composite of stroke, TIA, major bleed, or death compared to warfarin in adults with transthyretin cardiac amyloidosis and atrial fibrillation?
In patients with transthyretin cardiac amyloidosis and atrial fibrillation, NOACs and warfarin showed no significant difference in the combined risk of stroke, TIA, major bleeding, or death.
Mitrani et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: